Helene Arnion
Overview
Explore the profile of Helene Arnion including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
120
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chastagner D, Arnion H, Danthu C, Toure F, Picard N
Pharmacogenomics
. 2025 Feb;
25(16-18):707-718.
PMID: 40017426
Posttransplantation diabetes mellitus (PTDM) is a form of diabetes developed after solid organ or stem cell transplantation. This condition shares physiopathological traits with type 2 diabetes, including insulin resistance and...
2.
Mevizou R, Aouad H, Sauvage F, Arnion H, Pinault E, Bernard J, et al.
Pharmacol Res
. 2024 Oct;
209:107438.
PMID: 39357691
The toxicity of tacrolimus metabolites and their potential pharmacodynamic (PD) interactions with tacrolimus might respectively explain the surprising combination of higher toxicity and lower efficacy of tacrolimus despite normal blood...
3.
Brossier C, Jardou M, Janaszkiewicz A, Firoud D, Petit I, Arnion H, et al.
Life Sci
. 2024 Jun;
351:122792.
PMID: 38857657
Aims: Drug-induced enteropathy is often associated with the therapeutic use of certain glucuronidated drugs. One such drug is mycophenolic acid (MPA), a well-established immunosuppressant of which gastrointestinal adverse effects are...
4.
Faucher Q, Chadet S, Humeau A, Sauvage F, Arnion H, Gatault P, et al.
Metabolomics
. 2023 Sep;
19(9):83.
PMID: 37704888
Introduction: Ischemia-reperfusion injury (IRI) induces several perturbations that alter immediate kidney graft function after transplantation and may affect long-term graft outcomes. Given the IRI-dependent metabolic disturbances previously reported, we hypothesized...
5.
Aouad H, Faucher Q, Sauvage F, Pinault E, Barrot C, Arnion H, et al.
Pharmacol Res
. 2023 May;
192:106794.
PMID: 37187266
Introduction: Tacrolimus, an immunosuppressive drug prescribed to a majority of organ transplant recipients is nephrotoxic, through still unclear mechanisms. This study on a lineage of proximal tubular cells using a...
6.
Janaszkiewicz A, Toth A, Faucher Q, Arnion H, Vedrenne N, Barin-Le Guellec C, et al.
Biomed Pharmacother
. 2023 Feb;
160:114342.
PMID: 36739760
The Organic Anion Transporter 1 is a membrane transporter known for its central role in drug elimination by the kidney. hOAT1 is an antiporter translocating substrate in exchange for a-ketoglutarate....
7.
Faucher Q, Alarcan H, Sauvage F, Forestier L, Miquelestorena-Standley E, Nadal-Desbarats L, et al.
Transplantation
. 2022 Apr;
106(9):1831-1843.
PMID: 35442245
Background: Ischemia-related injury during the preimplantation period impacts kidney graft outcome. Evaluating these lesions by a noninvasive approach before transplantation could help us to understand graft injury mechanisms and identify...
8.
Berthier J, Benmameri M, Sauvage F, Fabre G, Chantemargue B, Arnion H, et al.
Xenobiotica
. 2020 Aug;
51(1):105-114.
PMID: 32820679
Mycophenolic acid (MPA) has become a cornerstone of immunosuppressive therapy, in particular for transplant patients. In the gastrointestinal tract, the liver and the kidney, MPA is mainly metabolized into phenyl-β-d...
9.
Burat B, Faucher Q, cechova P, Arnion H, Di Meo F, Sauvage F, et al.
FASEB Bioadv
. 2020 Mar;
1(9):561-578.
PMID: 32123851
Calcineurin inhibitors (CNI) are the pillars of immunosuppression in transplantation. However, they display a potent nephrotoxicity whose mechanisms remained widely unsolved. We used an untargeted quantitative proteomic approach (iTRAQ technology)...
10.
Bonnet S, Falkowski S, Deppenweiler M, Monchaud C, Arnion H, Picard N, et al.
Pharmacogenomics J
. 2020 Feb;
20(5):647-654.
PMID: 32015456
Genetic variations in CYP3A4, CYP3A5, and m-TOR could contribute to interpatient variability regarding m-TOR inhibitors pharmacokinetics or cellular effects. The purpose of this study was to evaluate the influence of...